ArticleSeminars in arthritis and rheumatism2026
Fibrosing myopathy in systemic sclerosis: Treatment response and clinical outcomes in a distinct subset.
Article in Seminars in arthritis and rheumatism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo characterize the clinical features, treatment response, and mortality of patients with systemic sclerosis (SSc) associated fibrosing myopathy.
methodsIn this retrospective study, we identified patients enrolled in the Johns Hopkins Scleroderma Center Research Registry with histopathological evidence of fibrosing myopathy. Data were collected regarding SSc features, treatment exposures, and outcomes. Muscle involvement was characterized using muscle enzyme levels, muscle magnetic resonance imaging (MRI) findings, electromyography (EMG) data, and histopathologic features.
results16 patients were included in the analysis. 14/16 patients (87.5%) received treatment specifically for muscle disease. Response based on muscle strength testing was evaluated at 6-12 months after treatment initiation. 9/16 patients (56.3%) had significant improvement, 4/16 (25%) showed no significant improvement, and 3/16 (18.8%) had inadequate follow-up. The most commonly used treatments were intravenous immunoglobulin, mycophenolate, and rituximab. After a mean follow-up time of 5.5 ± 4.7 years, 8/16 patients (50%) were deceased, with a cardiopulmonary cause of death in 4/8 (50%) of these patients. The baseline median CK value was 97 U/L (interquartile range 46-300 U/L). Myopathic changes were identified in 14/15 patients (93.3%) who had an EMG performed, while muscle edema was identified in 11/12 patients (91.7%) who underwent an MRI. A notable histopathological finding was myofiber atrophy in the perifascicular region in 9/16 patients (56.3%).
conclusionSSc-associated fibrosing myopathy is a distinct entity associated with a high mortality rate in our cohort of patients. Early recognition and initiation of treatment is important due to the potential for improvement in muscle strength.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.